Efficacy and Safety of Teriparatide Vs. Bisphosphonates and Denosumab Vs. Bisphosphonates in Osteoporosis Not Previously Treated with Bisphosphonates: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Arch Osteoporos

Publisher Springer

Date 2024 Sep 23

PMID 39312040

Authors

Mingnian Li

Zhuoqi Ge

Benqi Zhang

Li Sun

Zhongyuan Wang

Tao Zou

Qi Chen

Affiliations

Soon will be listed here.

Abstract

Objective: The systematic review and meta-analysis aimed to assess and compare the safety and efficacy of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in patients with osteoporosis who had not previously received bisphosphonates.

Methods: We conducted a search of published literature from inception to May 31, 2023, including databases such as PubMed, Embase, Cochrane Library, CNKI, SinoMed, VIP, and WanFang. The study only included head-to-head randomized controlled trials (RCTs) that compared teriparatide and denosumab with bisphosphonates to treat patients with osteoporosis. Fixed-effect model and random-effect model were used due to clinical heterogeneity. Meta-analysis was performed via Stata 17.0.

Results: A total of 6680 patients were enrolled across 23 eligible trials. The results of the meta-analysis showed that teriparatide was superior to bisphosphonates in decreasing the risk of fracture (risk ratio (RR) = 0.61, 95% confidence interval (CI) (0.51, 0.74), P < 0.001). Denosumab showed no benefit compared to bisphosphonates in reducing the risk of fracture in treating osteoporosis (RR 0.99, 95% CI (0.62, 1.57), P = 0.96). Compared with bisphosphonates, teriparatide and denosumab could significantly improve femoral neck, total hip, and lumbar spine bone mineral density (BMD) (P < 0.05). Furthermore, teriparatide and denosumab did not increase the incidence of adverse events (teriparatide vs. bisphosphonates, RR 0.92, 95% CI (0.79, 1.08), P = 0.32; denosumab vs. bisphosphonates, RR 0.98, 95% CI (0.95, 1.02), P = 0.37).

Conclusions: Teriparatide is superior to bisphosphonates in decreasing the risk of fracture in patients with osteoporosis. In addition, teriparatide and denosumab were more efficacious than bisphosphonates in increasing the percentage change in BMD at the femoral neck, total hip, and lumbar spine.

Citing Articles

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Beaudart C, Veronese N, Douxfils J, Amuthavalli Thiyagarajan J, Bolzetta F, Albanese P Osteoporos Int. 2025; .

PMID: 40047881 DOI: 10.1007/s00198-025-07440-1.

References

Rachner T, Khosla S, Hofbauer L . Osteoporosis: now and the future. Lancet. 2011; 377(9773):1276-87. PMC: 3555696. DOI: 10.1016/S0140-6736(10)62349-5. View

Clynes M, Harvey N, Curtis E, Fuggle N, Dennison E, Cooper C . The epidemiology of osteoporosis. Br Med Bull. 2020; 133(1):105-117. PMC: 7115830. DOI: 10.1093/bmb/ldaa005. View

Adachi J, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L . The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2002; 12(11):903-8. DOI: 10.1007/s001980170017. View

Tarride J, Adachi J, Brown J, Schemitsch E, Slatkovska L, Burke N . Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. Osteoporos Int. 2021; 32(9):1753-1761. PMC: 8387251. DOI: 10.1007/s00198-021-05877-8. View

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Khosla S, Bilezikian J, Dempster D, Lewiecki E, Miller P, Neer R . Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012; 97(7):2272-82. DOI: 10.1210/jc.2012-1027. View

McClung M . Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res. 2021; 33(4):775-791. DOI: 10.1007/s40520-020-01708-8. View

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

Blick S, Dhillon S, Keam S . Teriparatide: a review of its use in osteoporosis. Drugs. 2008; 68(18):2709-37. DOI: 10.2165/0003495-200868180-00012. View

10.

Girotra M, Rubin M, Bilezikian J . The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord. 2006; 7(1-2):113-21. DOI: 10.1007/s11154-006-9007-z. View

11.

Brixen K, Christensen P, Ejersted C, Langdahl B . Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol. 2004; 94(6):260-70. DOI: 10.1111/j.1742-7843.2004.pto940602.x. View

12.

Yuan F, Peng W, Yang C, Zheng J . Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019; 66:1-11. DOI: 10.1016/j.ijsu.2019.03.004. View

13.

Lyu H, Jundi B, Xu C, Tedeschi S, Yoshida K, Zhao S . Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2018; 104(5):1753-1765. PMC: 6447951. DOI: 10.1210/jc.2018-02236. View

14.

Wu J, Zhang Q, Yan G, Jin X . Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res. 2018; 13(1):194. PMC: 6090940. DOI: 10.1186/s13018-018-0865-3. View

15.

Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C . Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195. DOI: 10.7326/M22-0684. View

16.

Simpson E, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P . Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone. 2019; 130:115081. DOI: 10.1016/j.bone.2019.115081. View

17.

Wang W, Chen L, Ma W, You R . Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2023; 27(17):8253-8268. DOI: 10.26355/eurrev_202309_33586. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

19.

Body J, Gaich G, Scheele W, Kulkarni P, Miller P, Peretz A . A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87(10):4528-35. DOI: 10.1210/jc.2002-020334. View

20.

Cosman F, Eriksen E, Recknor C, Miller P, Guanabens N, Kasperk C . Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):503-11. DOI: 10.1002/jbmr.238. View